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SUMMARY 
Equine influenza is caused by two members of the genus 
Influenzavirus of the family Orthomyxoviridae. Diagnosis of 
influenzavirus infections of horses is based on virus isolation 
from horses with acute respiratory illness or on the 
demonstration of increased antibody titres of paired sera taken in 
the acute and convalescent stages of the disease. Ideally, both 
methods are used. 
Identification of the agent: Embryonated chicken eggs or cell 
cultures can be used for virus isolation from nasal swabs or 
washings from guttural pouches. Subtype 2 strains g/row equally 
well in both systems but subtype 1 strains are quite refractory to 
propagation in cell cultures. 
Viral growth is monitored by haemagglutination (HA) or in cell 
cultures by haemadsorption (HAD) using chicken or guinea pig 
erythrocytes (RBC). If HA or HAD are positive, isolates can be 
typed by haemagglutination-inhibition (HI) using strain-specific 
antisera. Isolates should always be sent to International 
Reference Laboratories (ΟΙΕ or WHO) for typing and strain 
collection. Samples which yield negative results (i.e. showing no 
HA or HAD after one passage) should be re-passaged. 
Serological tests: Diagnosis of influenzavirus infections can 
usually only be done by tests on paired sera; the first sample 
should be taken as soon as possible after the onset of clinical 
siffis and the second about two weeks later. Sera are 
heat-inactivated and pre-treated to reduce non-specific 
reactions. Antibody titres are determined by HI or single radial 
haemolysis (SRH). For SRH, serial dilution of sera is usually 
not required. HI and SRH give comparable results but SRH is 
superior if large numbers of sera are to be tested. 
Requirements for biological products: Equine influenza virus 
vaccines contain inactivated strains of subtypes 1 and 2 and 
induce humoral antibody responses after vaccination. 
A. DIAGNOSTIC TECHNIQUES 
Equine influenza is caused by two members of the genus Influenzavirus of the 
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family Orthomyxoviridae and consists of two subtypes, subtype 1 (H 7N 7) and 
subtype 2 (H 3N 8). These are not genuine pathogens for man, although horses can 
be infected with human influenza virus subtypes. These infections are unusual but 
can represent a potential biohazard to laboratory personnel. All influenza viruses 
are highly contagious for susceptible hosts, including embryonated hens' eggs and 
cell cultures. Care must therefore be taken during the handling of infected eggs or 
cultures (1). 
Reference strains should not be propagated in a diagnostic laboratory, and never at 
the same time or in the same place. AU working areas must be efficiently 
disinfected before and after virus manipulations, which should preferably be 
conducted within biohazard containment. 
It is important to obtain samples as soon as possible after the onset of clinical 
signs. These samples include nasal swabs or washings, swabs taken at endoscopy or 
washings from the guttural pouches. Swabs consist of cotton wool on applicator 
sticks which should be transferred to a vial containing transport medium 
immediately after use. This medium consists of phosphate buffered saline (PBS) 
containing 40% glycerol. If the samples are to be inoculated within 1-2 days, they 
may be held at 4°C but, if kept for longer, they should be stored at -60°C or below. 
Samples should also be transported at these temperatures. 
Only one sample is processed at a time. The liquid is expelled from the swab, 
which is suitably disposed of, and 0.1 ml of an antibiotic solution is added to 0.9 ml 
of the fluid. The remainder of the fluid is stored at -60°C. The antibiotic solution 
contains gentamycin (1 mg/ml), or penicillin (1000 units/ml) and streptomycin 
(500μg/ml). Samples treated with antibiotics are centrifuged at 1500 g for 15 
minutes to remove bacteria and debris; the supernatant fluids are used for 
inoculation. 
1. Identification of the agent 
Embryonated hens9 eggs 
Fertile eggs are set in a humidified incubator at 38°C and turned twice daily; 
after 10-11 days, they are examined by candling. Only live embryonated eggs 
are selected for use. The area above the air sac is cleansed with alcohol and a 
small hole drilled through the shell. Three eggs/sample are inoculated (0.1 ml) 
into the amniotic cavity. The syringe is withdrawn about 1 cm and a further 0.1 
ml inoculated into the allantoic cavity. The hole is sealed with wax and the 
eggs incubated at 34-37°C for 2-3 days. 
The eggs are then transferred to 4°C overnight to kill the embryos and to 
reduce bleeding at harvest. The shells are disinfected and the allantoic fluid is 
harvested by pipette, each harvest being kept separate. These are tested 
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for HA activity using a 0.5% suspension of chicken erythrocytes (RBC) or 
0.4% guinea pig RBC. If there is no HA activity, aliquots of each harvest are 
pooled and re-passaged into further eggs. All HA positive samples are divided 
into aliquots and stored at -70°G; 1 aliquot is titrated for HA immediately and 
if it has a titre of 1:16 or more, the isolate is typed. Non-agglutinated RBC 
form a "stream" when the tube or plate is tilted. 
Cell cultures 
Cultures of the Madin-Darby canine kidney cell line (MDCK, ATCC CCL34) 
may be used to isolate equine influenza viruses. The cells are grown in tubes 
and infected in triplicate when grown to confluence with 0.25-0.5 ml of each 
sample, processed as described above. The cultures are maintained with 
medium containing 2 μg/ml trypsin, and examined daily for evidence of 
cytopathic effect (CPE). If positive, or after 7 days in any case, the supernatant 
fluids are tested for HA. Fluids with titres of 1:16 or more are typed 
immediately. Negative fluids are re-passaged. 
Alternatively, the cells are screened for evidence of haemadsorption (HAD). 
This procedure detects expression of viral antigens at the cell surface. The 
medium is removed from the cultures and the tubes washed with PBS. One to 
two drops of a 50% suspension of chicken or guinea pig RBC are added, the 
tubes rotated carefully, and kept at room temperature for 30 minutes. 
Unbound RBC are washed off with PBS and the cultures examined 
microscopically for evidence of HAD. 
Typing of new isolates of equine influenza viruses is best done by HI using 
specific antisera, prepared preferably in ferrets. Isolates may first be treated 
with Tween-ether, which destroys viral infectivity and reduces the risk of 
cross-contaminations. 
For HI, both macro- and micro-tests may be used. The antigens are diluted to 
final HA titres of 1:4 or 1:8. Antisera, treated to reduce non-specific 
haemagglutinins, are serially diluted in PBS, antigen is added and the mixtures 
reacted for 30 minutes at room temperature. The RBC (0.5% chicken or 0.4% 
guinea pig) are added, gently mixed and allowed to stand at room temperature 
for 30 minutes. The volumes of the microtest are 0.025 ml for PBS, sera and 
antigen, respectively, followed by 0.05 ml for the RBC suspension. In the 
macrotest, 0.5 ml volumes are used throughout. The HI titres are read as the 
highest dilution of serum giving a complete inhibition of agglutination, i.e., the 
RBC form a "stream" when the plates are tilted. Incomplete inhibition is 
always scored as agglutination. All isolates should be sent to the International 
Reference Centres designated by ΟΙΕ and WHO. 
Standard antigens must be titrated in parallel with these tests and should 
include: subtype 1 (A/eq/Prague/56) and subtype 2 (A/eq/Miami/63; 
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A/eq/Fontainebleau/79; A/eq/Kentucky/81; or A/eq/Solvalla/79). Additionally, 
recent isolates from the same geographical area should be included if 
available. The standard antigens should be treated with Tween-ether to avoid 
cross-contamination. Test antigens and standard antigens are always 
back-titrated to confirm their antigen content. 
Neuraminidase 
Typing of neuraminidase requires specific antisera and no routine technique is 
available. Such typing is therefore best done in reference laboratories. 
2. Serological tests 
Infections are detected by conducting serological tests on paired sera to show a 
rise in antibody titre. These tests should be carried out whether virus isolation 
has been attempted or not. Two methods exist, each equally efficient and 
widely used. The complement fixation (CF) test can also be applied but the 
technique is not standardized. 
a) Haemagglutination-inhibition (HI) test 
The standard antigens are described above. If available, isolates from 
recent cases should be included. The antigen is first treated with 
Tween-ether. Lyophilised treated antigens for equine influenza viruses are 
available from the ΟΙΕ Reference Centre. The test is best done in 
microtitre plates using the appropriate dilution equipment. 
Sera are pre-treated to remove non-specific haemagglutinins and are 
inactivated by heating at 56°C for 30 minutes. Pre-treatments include the 
use of one of the following: (i) Kaolin and RBC absorption, (ii) Potassium 
periodate, or (iii) V. cholerae receptor-destroying enzyme (RDE). All 
three procedures yield similar results. The treated sera are diluted in PBS, 
antigen with a titre of 1:4 or 1:8 is added, and these are kept at room 
temperature for 30 minutes after gentle mixing. RBC are added and the 
test is read 30 minutes later. The HI titres are the highest dilutions of 
serum that completely inhibit HA. Titre increases of 4-fold or more 
between paired sera indicate recent infections. 
b) Single radial haemolysis (SRH) 
In this test, viral antigens are coupled to fixed RBC that are suspended in 
agarose containing guinea pig complement (C). Wells are punched in the 
agarose and filled with test sera. Influenza antibodies and C lyse the 
antigen-coated RBC, resulting in a clear, haemolytic zone around the well; 
the size of this zone can be measured. 
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Special immunodiffusion plates (Hyland; Miles Scientific) may be used for 
the assay, but simple Petri dishes are also suitable. Sheep RBC are 
collected into Alsever's solution and washed 3 times. The C can be 
obtained commercially, or normal guinea pig serum can be used. The 
antigens are allantoic fluids or purified preparations; the strains used are 
the same as for the HI tests. The viruses are coupled to RBC by potassium 
periodate or, in the case of purified preparations, by chromic chloride. 
The coupled antigen-RBC preparations are mixed with C, together with a 
1% solution of agarose (low melting grade) in PBS. Care must be taken 
that the temperature not be allowed to rise above 42°C at any time. The 
mixture is poured into plates and left overnight at 4°C. Wells of 2-3 mm in 
diameter and 12 mm apart are punched in the solidified agarose 6 mm 
from the edge of the plates. Such plates may be stored at 4°C for several 
weeks. Plates are prepared for each antigen and pre-tested with known 
positive and negative antisera. 
For safety reason, all sera are heat-inactivated (at 56°C for 30 minutes) but 
no further treatment is necessary. Paired sera should be assayed in 
duplicate on the same plate; all sera are tested in a plate containing all 
components except virus. Sera that show haemolytic activity for sheep 
RBC must be pre-absorbed with sheep RBC. Zones of lysis should be 
clear, and not hazy or translucent. All clear zones should be measured and 
the area of haemolysis calculated. Differences in diameter between 
duplicate samples must be less than 1.5-fold. In paired sera, differences in 
diameters of 2-fold or more are considered significant for infection. Sera 
with differences between 1.5-fold and 2-fold should be re-tested. 
B. REQUIREMENTS FOR BIOLOGICAL PRODUCTS 
Equine influenza virus vaccines consist of inactivated virus subtypes 1 and 2, or 
their subunits, that induce sufficient humoral antibody responses in seronegative 
horses that are susceptible to these agents (2). 
1. Seed management 
a) Characteristics 
The vaccine must contain the following influenza virus strains: 
Subtype 1: A subtype 1 strain, such as A/eq/Prague/1/56; but other 
subtype 1 strains may be used. 
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Subtype 2: Two subtype 2 strains are available: 
i) One classical strain (i.e. isolated before 1979), such as 
A/eq/Miami/1/63; but other strains may be used if a very close 
antigenic relationship to the above strain has been demonstrated. 
ii) One strain isolated following the antigenic drift of 1979-81, such as 
A/eq/Fontainebleau/79, A/eq/Kentucky/81 or A/eq/Solvalla/79. Other 
strains may be used if they are shown to be either closely related to the 
three preceding strains or of local importance. 
The prevalence and antigenic variation of current isolates of equine 
influenza viruses must be monitored continuously, preferably by ΟΙΕ or 
WHO Reference Laboratories. If the results of such studies indicate a 
significant antigenic drift, drifted strains should also be included. 
b) Culture 
Virus strains may be obtained from ΟΙΕ or WHO Centres or from the 
ATCC (American Type Culture Collection, Rockville, MD 26852, USA). 
The strains are propagated in the allantoic cavity of 10-day-old 
embryonated hens' eggs. All manipulations must be conducted separately 
for each strain. Viral growth is monitored by HA tests. Passaged virus is 
identified by serological tests, such as HI or SRH. Seed virus is divided 
into aliquots and stored in freeze-dried form or at -70°C. 
2· Manufacture 
Production is based on a seed-lot sytem that has been validated with respect to 
the characteristics of the vaccine strains. Each strain of virus is inoculated 
separately into the allantoic cavity of 9- to 11-day-old embryonated hens' eggs 
from a healthy flock. The eggs are incubated at a suitable temperature for 2-3 
days and the allantoic fluid is collected. The viral suspensions of each strain 
are collected separately and inactivated. If necessary, they may be purified. 
Suitable adjuvants and antimicrobial preservatives may be added. 
3. In-process control 
In-process controls include: 
a) Identity of virus strains (tested by HI), 
b) Sterility, 
c) Virus titre (titration in embryonated eggs), and 
d) Haemagglutination (tested by HA). 
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4. Batch control 
a) Sterility 
Tests for sterility and freedom from contamination of biological materials 
may be found in the chapter on general information. 
b) Safety 
Using not less than 2 horses, each horse is inoculated intramuscularly at 2 
different sites with the dose of vaccine specified by the manufacturer; 
these are repeated 4 weeks later. The animals are kept under observation 
for 10 days after the second injections. No abnormal local or systemic 
reactions should ensue. 
To test for completeness of inactivation, inoculate 0.2 ml of the vaccine 
into the allantoic cavity of each of 10 embryonated hens's eggs, 9-11 days 
old. Incubate at a suitable temperature for 3 days. The death of any 
embryo within 24 hours of inoculation is considered to be non-specific and 
the embryo is discarded. The allantoic fluids are collected, pooled and 
passaged into further eggs in the same way. After 4 days' incubation, the 
allantoic fluids of these eggs should possess no HA activity. 
c) Potency 
Horses 
To test a vaccine for efficacy in horses, inject a volume correponding to 1 
vaccine dose by the recommended route into each of 5 susceptible 
seronegative horses. After the period stated on the label as that between 
the first and second injection, inject a volume corresponding to the second 
dose of vaccine. 
Collect 2 blood samples from each animal, the first 1 week after the first 
vaccination and the second 2 weeks after the second vaccination. Separate 
the serum from each sample. Inactivate each serum by heating at 56°C for 
30 minutes. To 1 volume of each serum add 3 volumes of PBS pH 7.4 and 
4 volumes of a 25% (w/v) suspension of kaolin R in the same buffer 
solution. Shake each mixture at room termperature for 10 minutes. 
Centrifuge, collect the supernatant fluid and mix it with a concentrated 
suspension of chicken RBC. Allow to stand at 37°C for 1 hour and 
centrifuge. The dilution of serum that results is now 1:8. Other treatments 
of sera may also be used (see section 2). 
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Perform tests on each serum using, respectivly, the antigen or antigens 
prepared from the strain or strains used in the production of the vaccine. 
Using each diluted serum, prepare a series of 2-fold dilutions. To 0.025 ml 
of each of the latter, add 0.025 ml of a suspension of each antigen, 
respectively treated with ether or Tween-ether and containing 4 
haemagglutinating units (HAU). Allow the mixtures to stand at room 
temperature for 30 minutes and add 0.05 ml of a 0.5% suspension of 
chicken RBC. Allow to stand at room temperature for 1 hour and note the 
last dilution of serum that still completely inhibits HA. 
The antibody titre of each serum taken after the second vaccination in each 
test calculated for the original serum is not less than 1:64, taking into 
account the pre-dilution of 1:8. If the titre found for any horse after the 
first vaccination indicates that there has been an anamnestic response, that 
result is not taken into account. A supplementary test is carried out, as 
described above, using the number of horses that showed an anamnestic 
response. 
If tests for potency in horses have been carried out with satisfactory results 
on a representative batch of vaccine, this test may be omitted as a routine 
control on other batches of vaccine prepared using the same seed-lot 
system, subject to agreement by the National Control Authority. 
Guinea pigs 
Into each of 10 guinea pigs free from specific antibodies, inject the dose 
stated on the label. Twenty-one days later, collect blood samples and 
separate the serum. Inactivate each serum by heating at 56°C for 30 
minutes and treat the sera as described above for horse sera. 
Perform the tests on each serum using, respectively, the antigen or antigens 
prepared from the strain or strains used in the production of the vaccine. 
Using each diluted serum, prepare a series of 2-fold dilutions. To 0.025 ml 
of each dilution, add 0.025 ml of a suspension of each antigen respectively 
treated with ether or Tween-ether and containing 4 HAU. Allow the 
mixtures to stand at room temperature for 30 minutes and add 0.05 ml of a 
0.5% suspension of chicken RBC. Allow to stand at room temperature for 
1 hour and note the last serum dilution that still completely inhibits HA. 
The antibody titre of each serum in each test before mixture with the 
suspension of antigen and RBC should not be less than 1:16, taking into 
account pre-dilutions by treatment. 
The European Pharmacopoeia may also be used as a reference for the 
control of equine influenza virus vaccines. 
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